- Home
- CTNM vs ATOS Comparison
CTNM vs ATOS Comparison
Compare CTNM & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- ATOS
- Stock Information
- Founded
- CTNM 2009
- ATOS 2009
- Country
- CTNM United States
- ATOS United States
- Employees
- CTNM N/A
- ATOS N/A
- Industry
- CTNM
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- CTNM
- ATOS Health Care
- Exchange
- CTNM Nasdaq
- ATOS Nasdaq
- Market Cap
- CTNM 122.9M
- ATOS 112.5M
- IPO Year
- CTNM 2024
- ATOS 2012
- Fundamental
- Price
- CTNM $3.84
- ATOS $0.83
- Analyst Decision
- CTNM Strong Buy
- ATOS Strong Buy
- Analyst Count
- CTNM 4
- ATOS 3
- Target Price
- CTNM $22.50
- ATOS $6.17
- AVG Volume (30 Days)
- CTNM 222.5K
- ATOS 1.5M
- Earning Date
- CTNM 08-12-2025
- ATOS 08-11-2025
- Dividend Yield
- CTNM N/A
- ATOS N/A
- EPS Growth
- CTNM N/A
- ATOS N/A
- EPS
- CTNM N/A
- ATOS N/A
- Revenue
- CTNM N/A
- ATOS N/A
- Revenue This Year
- CTNM N/A
- ATOS N/A
- Revenue Next Year
- CTNM N/A
- ATOS N/A
- P/E Ratio
- CTNM N/A
- ATOS N/A
- Revenue Growth
- CTNM N/A
- ATOS N/A
- 52 Week Low
- CTNM $3.35
- ATOS $0.55
- 52 Week High
- CTNM $22.00
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- ATOS 49.96
- Support Level
- CTNM N/A
- ATOS $0.77
- Resistance Level
- CTNM N/A
- ATOS $0.92
- Average True Range (ATR)
- CTNM 0.00
- ATOS 0.04
- MACD
- CTNM 0.00
- ATOS -0.00
- Stochastic Oscillator
- CTNM 0.00
- ATOS 45.69
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.